Inhibition of the protein Ezh2 causes chronic myelogenous leukemia (CML) stem cells to die. Adding drugs that target this protein to imatinib (Gleevec) or other BCR-ABL blockers could result in a cure for this disease.
Pregnancy screening rates before teratogenic exposures are low for female adolescent patients with acute leukemia and those with ER visits including abdominal/pelvic CT.
Hematopoietic stem cell transplantation (HCT) is found to increase expression of a genetic code used to make proteins, leading to a biological aging of immune cells equivalent to 30 years of chronological age.
Research using cancer cell lines demonstrated that supplementing standard epigenetic therapy with vitamin C enhanced the drug's antineoplastic action.
The population-based EUTOS registry demonstrated high overall and progression-free survival rates among patients with chronic myeloid leukemia.
Blood stem cells derived from donor bone marrow resulted in better self-reported psychological well-being and fewer GVHD symptoms.
Dasatinib and nilotinib are associated with similar response rates and survival outcomes in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP).
For patients with chronic myeloid leukemia treated with lifelong targeted therapies, social support is crucial for maintaining psychological well-being.
Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) plus ponatinib appears to be superior to hyper-CVAD plus dasatinib for the frontline treatment of patients with Philadelphia chromosome-positive ALL.
Patients with acute myeloid leukemia (AML) harboring mutations in the TP53 gene have worse complete remission rates and durations and overall survival regardless of age or the type of treatment received.
Tyrosine Kinase Inhibitor Therapy Can Be Safely Stopped in Select Patients With CML in Chronic PhaseJuly 29, 2016
A high percentage of patients with CML treated with TKIs achieve deep molecular responses and can safely stop therapy. Initials results of the EURO-SKI trial define prognostic markers that indicate durability of deep molecular responses after stopping TKI therapy.
Mogamulizumab induced an encouraging response rate in patients with relapsed/refractory adult T-cell leukemia/lymphoma.
Telomere length is predictive for determining which children treated for AML are at highest risk for delayed recovery, a finding that may have significant implications for treatment-related morbidity and mortality.
In the era of tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation, the life expectancy of patients with CML is approaching that of the general population.
A study examined the impact of post-transplant maintenance TKIs on patients with Ph+ acute lymphoblastic leukemia and chronic myeloid leukemia.
Recently Identified Biomarkers Found to Warn of Chronic Graft-vs-Host Disease in Marrow Transplant PatientsJuly 01, 2016
Researchers recently identified CXCL10, a protein that could act as a biomarker for chronic graft-versus-host disease (cGVHD), a long-term adverse effect that develops in some patients after undergoing blood and bone marrow transplant.
Ibrutinib treatment for chronic lymphocytic leukemia with the deletion of chromosome 17p (del17p CLL) increases the percentage of patients alive at 30 months over other therapies for del17p CLL.
In a randomized phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with ALL whose disease had relapsed following standard therapies, qualified for stem cell transplants after treatment with the drug.
Event-free survival for adult patients with ALL has improved from 40% to 73% with the implementation of the NOPHO ALL 2008 protocol in July 2008.
Deep and durable remissions were produced by the combination of SGN-CD33A and hypomethylating agents among patients with acute myeloid leukemia (AML).
Overall survival for patients with acute lymphoblastic leukemia (ALL) was nearly doubled to 7.8 months from 4.0 months by treating patients with blinatumomab compared with standard of care.
Pediatric patients with ALL treated with methotrexate can experience challenges with mental flexibility and organization compared with expectations from the general population.
New research indicates that rituximab maintenance therapy can extend progression-free survival in patients with chronic lymphocytic leukemia achieving at least a partial response to induction therapy with rituximab and chemotherapy.
Researchers revealed a pathway in cell culture and mice by which salicylic acid decreases inflammation and by which salicylic acid and diflunisal decrease cancerous growth.
Prognostic Index Will Improve Clinical Practice Management of Patients With CLL and in Clinical TrialsJune 10, 2016
An international consortium devised an international prognostic index for chronic lymphocytic leukemia (CLL-IPI) that combines genetic, biochemical, and clinical parameters into a prognostic model to enable more targeted management of patients with CLL.
The FLT3 tyrosine kinase is the most frequent mutation found in AML, and targeting CDK6 with palbociclib may be an effective strategy against AML.
The US FDA has granted Priority Review to ofatumumab used in combination with fludarabine and cyclophosphamide for the treatment of chronic lymphocytic leukemia.
Response to T-cell Immunotherapy Promising for Patients With Advanced B-cell Acute Lymphocytic LeukemiaMay 20, 2016
Remission was achieved for 27 of 29 patients with advanced B cell acute lymphocytic leukemia (ALL) in an early phase trial of CAR T cells.
Cancer stem cells that drive tumor growth were halved by MEDI-551, an experimental antibody treatment for multiple myeloma, according to results of a small preliminary clinical trial.
Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomasApril 21, 2016
[Blood and Lymphatic Cancer: Targets and Therapy] This research examines the clinical trial data using idelalisib as monotherapy or in combination with rituximab for the treatment of indolent B-cell malignancies.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Patient Navigation Reduces Delays in Diagnostic Resolution
- Fee-for-service Medicare Plans Linked to Improved Care During Last Year of Life
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|